After the Federal Circuit vacated and remanded the district court’s non-obviousness determination, the district court again found that Teva failed to show, by clear and convincing evidence, that the claims of Janssen’s patent...more
8/6/2025
/ CAFC ,
Life Sciences ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Remand
Procedural History -
Sanofi-Aventis Deutschland GMBH v. Mylan Pharmaceuticals Inc. is an appeal from a final written decision in an inter partes proceeding (“IPR”) of the Patent Trial and Appeal Board (“PTAB”) that found...more
Procedural History -
Arbutus Biopharma Corp. v. Modernatx, Inc. is an appeal from a final written decision in an inter partes proceeding of the Patent Trial and Appeal Board (“PTAB”) that found claims 1-22 of U.S. Patent...more